Cooper Companies Inc's COO Q1 FY22 revenues increased 16% Y/Y to $787.2 million, up 19% in constant currency and 13% organically, beating the consensus of $744.34 million.
- The CooperVision (CVI) segment revenue increased 11% to $561.5 million, and CooperSurgical (CSI) revenue up 30% to $225.7 million.
- Non-GAAP EPS of $3.24, up 2% Y/Y, beat the consensus of $3.10.
- The adjusted gross margin was 67%, down from 68% last year, driven primarily by currency. Adjusted operating margin compressed to 25% from 27% in last year's first quarter, driven primarily by currency and higher investing.
- Net debt outstanding at quarter-end was $2.9 billion due to the acquisition of Generate Life Sciences. Adjusted leverage ratio was 2.71x.
- Related: CooperCompanies Scoops Up Cook Medical's Reproductive Health Business For $875M.
- Cash provided by operations of $166.0 million offset by capital expenditures of $57.1 million resulted in a free cash flow of $108.9 million.
- Guidance: Cooper Companies expects FY22 sales of $3.261 billion - $3.329 billion (organic growth of 6.5% to 8.5%), compared to the consensus of $3.29 billion.
- Earlier, the company guided sales of $3.03 billion - $3.09 billion.
- The outlook includes CVI segment revenue $2.22 billion - $2.26 billion and CSI segment sales of $1.04 billion - $1.06 billion.
- For FY22, the company expects adjusted EPS of $13.70 - $14.20, versus the consensus of $14.36 and prior guidance of $13.60 - $14.00.
- Price Action: COO shares closed 0.34% higher at $417.14 on Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in